View in EDS HTML Full Text PDF Full Text

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Authors: Bauer J; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Köhler N; Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.; CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany., Maringer Y; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Bucher P; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany., Bilich T; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Zwick M; Department of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.; Faculty of Biology, Albert-Ludwigs-Universität, Freiburg, Germany., Dicks S; Faculty of Biology, Albert-Ludwigs-Universität, Freiburg, Germany.; Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Nelde A; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Dubbelaar M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany., Scheid J; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany., Wacker M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Heitmann JS; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Schroeder S; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany., Rieth J; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany., Denk M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tübingen, Tübingen, Germany., Richter M; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tübingen, Tübingen, Germany., Klein R; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Bonzheim I; Department of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany., Luibrand J; Department of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany., Holzer U; Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany., Ebinger M; Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany., Brecht IB; Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany., Bitzer M; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tübingen, Tübingen, Germany.; Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany., Boerries M; Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site, Freiburg, Germany., Feucht J; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany., Salih HR; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Rammensee HG; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tübingen, Tübingen, Germany., Hailfinger S; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Walz JS; Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.
Source: Nature communications [Nat Commun] 2022 Oct 27; Vol. 13 (1), pp. 6401. Date of Electronic Publication: 2022 Oct 27.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-022-33746-3